Identifying predictors of racial disparity in treatment and mortality among patients diagnosed with breast cancer in South Carolina and geospatial investigation of breast cancer patient navigation
确定南卡罗来纳州乳腺癌患者治疗和死亡率种族差异的预测因素以及乳腺癌患者导航的地理空间调查
基本信息
- 批准号:9978735
- 负责人:
- 金额:$ 9.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-15 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAdjuvantAffectAgeAnxietyAreaAwardBasic ScienceBreast Cancer PatientBreast Cancer TreatmentCancer CenterCancer PatientCharacteristicsCombined Modality TherapyCommunicationComplexDataDatabasesDevelopmentDiagnosisDiagnosticEmployeeFellowshipFemale Breast CarcinomaGeographic FactorGeographic Information SystemsGeographic LocationsGrantHealthHospitalsIncidenceIndividualInterventionInvestigationKnowledgeLinkMedicaidMedicalMentorsMethodologyMethodsMinorityModelingNeighborhoodsOncologistOperative Surgical ProceduresPatientsPharmacy facilityPhasePhysiciansPopulationPostdoctoral FellowPreparationPrivatizationProductivityPublicationsRaceRandomized Controlled TrialsResolutionSample SizeSmall-Area VariationsSouth CarolinaTimeTrainingTranslatingTrustUnited StatesWait TimeWomanbreast cancer survivalcancer carechemotherapydisparity reductionevidence baseexperiencehormone receptor-positivehormone therapyimprovedinsurance planlow socioeconomic statusmalignant breast neoplasmmortalitymortality disparitymultilevel analysisneoplasm registrypre-doctoralracial disparityracial minorityskillstreatment disparityuptake
项目摘要
Delay in treatment initiation contributes to higher mortality among Black women despite lower incidence of
breast cancer (BrCa) among Black compared to White women. Survival studies show that a delay of two
months has been linked with a less favorable survival among BrCa cases. The use of Adjuvant Hormonal
Therapy (AHT) has been shown to improve both short- and long-term survival among Hormone Receptor
Positive (HR+) BrCa patients worldwide as it reduces BrCa mortality and reoccurrence. The advantages of
AHT notwithstanding, 10-30% of eligible BrCa patients never start treatment with AHT and many who start
AHT never complete the treatment leading to reoccurrence and increased mortality. This lack of initial uptake
and adherence to AHT is worse among Blacks compared to Whites. Effective reduction of disparities in
treatment delays and mortality among racial minorities will require the identification of the mechanisms by
which disparities occur particularly, studying neighborhood-level factors that have been shown to affect the
odds of receipt of BrCa treatments among Black women. For this application, I propose to assess racial
disparities in BrCa treatment and mortality in South Carolina (SC) utilizing data that was derived from all
female BrCa cases over eight years from the SC Central Cancer Registry linked with administrative medical
and pharmacy claims data for both publicly insured and privately insured BrCa patients. I will assess the
complex interplay between 1) geographic factors, 2) racial disparities 3) Geographical Information System
(GIS) mapping, 4) survival methods and 5) multi-level models to identify predictors of treatment delays and
mortality that can be intervened upon. GIS methods have not been utilized to specifically identify individual-
and neighborhood-level characteristics that may contribute to BrCa mortality among blacks within the context
of multilevel survival modelling; this has the potential to allow for the application of evidence-based approaches
to reduce disparities. This project has 3 aims: 1) to assess racial disparities in treatment delays and the
utilization of AHT among patients diagnosed with breast cancer (Pre-Doctoral and completed); 2) to identify
predictors of dissimilarity in breast cancer related survival by health regions among Black women in SC
utilizing multilevel survival models and GIS methodologies (Pre-Doctoral and yet to be completed); 3) to
assess if neighborhood-level factors modify the effect of patient navigation on uptake of initial recommended
breast cancer care and time to diagnostic resolution among minority populations (Post-Doctoral direction). The
F99 phase of this fellowship award will provide the necessary training and mentoring to further my knowledge
and skill in 1) disparities, 2) survival, 3) multi-level, 4) GIS, and 5) geospatial analyses. The K00 phase will
expose me to 1) interventional analyses such as cancer patient navigation, 2) Randomized Controlled Trials
and 3) enhance my scholarly productivity and professional development during this fellowship, including
preparation and submission of grants and publications.
治疗开始的延迟导致黑人妇女死亡率较高,尽管其发病率较低。
乳腺癌(BrCa)在黑人与白色妇女之间的比较。生存研究表明,
与BrCa病例中较不利的生存期有关。辅助激素的使用
治疗(AHT)已被证明可以改善激素受体
全球BrCa阳性(HR+)患者,因为它降低了BrCa死亡率和复发率。的优点
尽管有AHT,但10-30%符合条件的BrCa患者从未开始AHT治疗,
AHT从未完成治疗,导致复发和死亡率增加。这种缺乏初始吸收
与白人相比,黑人对AHT的依从性更差。有效缩小性别差距
少数民族的治疗延误和死亡率将需要确定机制,
特别是哪些差异发生,研究邻里水平的因素,已被证明会影响
黑人妇女接受BrCa治疗的几率。对于这项申请,我建议评估种族
利用来自所有研究的数据,在南卡罗来纳州(SC),
来自SC中央癌症登记处的8年以上女性BrCa病例与行政医疗相关
以及公共保险和私人保险BrCa患者的药房索赔数据。我将评估
1)地理因素,2)种族差异,3)地理信息系统之间的复杂相互作用
(GIS)映射,4)生存方法和5)多水平模型,以确定治疗延迟的预测因子,
可以干预的死亡率。地理信息系统方法尚未用于具体确定个人-
和邻里水平的特点,可能有助于在黑人中的BrCa死亡率的背景下,
多层次生存建模;这有可能允许应用循证方法
减少不平等。该项目有3个目标:1)评估治疗延迟的种族差异,
在诊断为乳腺癌的患者中使用AHT(博士前和完成); 2)识别
南卡罗来纳州黑人妇女健康地区乳腺癌相关生存率差异的预测因素
利用多层次生存模型和GIS方法(博士预科,尚未完成); 3)
评估社区水平因素是否会改变患者导航对初始推荐摄入量的影响
乳腺癌护理和少数民族人群中诊断解决的时间(博士后方向)。的
F99阶段的奖学金将提供必要的培训和指导,以促进我的知识
和技能1)差异,2)生存,3)多层次,4)地理信息系统,和5)地理空间分析。K 00阶段将
让我接触1)干预性分析,如癌症患者导航,2)随机对照试验
以及3)在此期间提高我的学术生产力和专业发展,包括
准备和提交赠款和出版物。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Geographic Variation in Human Papillomavirus Vaccination Initiation and Completion Among Young Adults in the U.S.
- DOI:10.1016/j.amepre.2020.09.005
- 发表时间:2021-03
- 期刊:
- 影响因子:5.5
- 作者:Adjei Boakye E;Babatunde OA;Wang M;Osazuwa-Peters N;Jenkins W;Lee M;Kim M
- 通讯作者:Kim M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Oluwole Adeyemi Babatunde其他文献
Oluwole Adeyemi Babatunde的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Oluwole Adeyemi Babatunde', 18)}}的其他基金
Identifying predictors of racial disparity in treatment and mortality among patients diagnosed with breast cancer in South Carolina and geospatial investigation of breast cancer patient navigation
确定南卡罗来纳州乳腺癌患者治疗和死亡率种族差异的预测因素以及乳腺癌患者导航的地理空间调查
- 批准号:
9435745 - 财政年份:2017
- 资助金额:
$ 9.51万 - 项目类别:
Identifying predictors of racial disparity in treatment and mortality among patients diagnosed with breast cancer in South Carolina and geospatial investigation of breast cancer patient navigation
确定南卡罗来纳州乳腺癌患者治疗和死亡率种族差异的预测因素以及乳腺癌患者导航的地理空间调查
- 批准号:
9567963 - 财政年份:2017
- 资助金额:
$ 9.51万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 9.51万 - 项目类别: